{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/neuropathic-pain-drug-treatment/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field fa48a3dc-e80c-42e2-89c6-6c8c03bc2bc0 --><h2>Changes</h2><!-- end field fa48a3dc-e80c-42e2-89c6-6c8c03bc2bc0 -->","summary":null,"htmlStringContent":"<!-- begin item 8ce48a44-e481-445e-9946-8d1cc8899917 --><!-- begin field b0cd713f-4e42-4033-aff0-ccb405543c34 --><p><strong>December 2020 </strong>— minor update. Severe respiratory depression added as an adverse effect of pregabalin in line with updated manufacturer's SPC.</p><p><strong>August 2020 </strong>— minor update. Broken URL link updated.</p><p><strong>February 2020 </strong>— reviewed. A literature search was conducted in January 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been no major changes to the recommendations. The scope of the topic has been updated to clarify that it does not cover the treatment of sciatica.  </p><!-- end field b0cd713f-4e42-4033-aff0-ccb405543c34 --><!-- end item 8ce48a44-e481-445e-9946-8d1cc8899917 -->","topic":{"id":"b1f9c908-6cb6-5afd-a737-0a621c6232d0","topicId":"35e3d915-8243-4418-a7dd-6590d8ca5c85","topicName":"Neuropathic pain - drug treatment","slug":"neuropathic-pain-drug-treatment","lastRevised":"Last revised in December 2020","chapters":[{"id":"0c243e96-3697-5ee3-98c7-9ffecf07f2af","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94d784c6-0537-5187-a548-a95e6ad2f899","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f0b9b63a-bd52-51b6-8eda-cb26c9f551a0","slug":"changes","fullItemName":"Changes"},{"id":"2e3e3fff-20af-56ab-b8f8-a9ee4f14f833","slug":"update","fullItemName":"Update"}]},{"id":"80218328-d006-5b34-a01a-0ef4dbeaf7d5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"22989c5e-df85-5aba-bd66-8c44723e59d7","slug":"goals","fullItemName":"Goals"},{"id":"722de221-9258-5985-8a02-c088cf258a12","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"bf3b0c22-2d82-5464-bf76-bc066dae256f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c6576f2f-fd04-5900-a5e1-517233523e2c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"dd2de31a-79d5-5c20-9132-c99c41c12822","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"148cc621-37d8-5264-a358-c380fcfb4223","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"eddf36b3-7bc8-53c9-9c59-fa36b809f229","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"025ef443-81b5-565d-8240-d76615c27e55","slug":"definition","fullItemName":"Definition"},{"id":"3704349e-d3ae-5a8b-ba94-9da5282ed77f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e18339e8-95d0-582f-ad51-0614dae8f855","slug":"complications","fullItemName":"Complications"},{"id":"9b552f08-01aa-583d-900b-9cbdc90fe28d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"21d7485a-b855-5ba4-82bc-ca3154184325","fullItemName":"Management","slug":"management","subChapters":[{"id":"bad22859-57ae-5c1c-a944-c3d9fef6d160","slug":"neuropathic-pain-drug-treatment","fullItemName":"Scenario: Neuropathic pain - drug treatment"}]},{"id":"0d8cb386-e038-5d6f-83af-81664da82cca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a91a8f28-db46-58e8-9df7-f30be0f00f2b","slug":"amitriptyline","fullItemName":"Amitriptyline"},{"id":"382b9603-7b46-57d1-9b07-fa743886796e","slug":"pregabalin","fullItemName":"Pregabalin"},{"id":"498f1249-e619-5b41-b42b-1a914239d269","slug":"gabapentin","fullItemName":"Gabapentin"},{"id":"201a6fcc-11c6-5f00-b820-7fa69ee8b95d","slug":"duloxetine","fullItemName":"Duloxetine"},{"id":"56e4231d-ab93-5963-bc8a-989240189179","slug":"capsaicin-cream","fullItemName":"Capsaicin cream"},{"id":"01a263c7-9fe1-5a29-95ec-24e56c0c1bc9","slug":"tramadol","fullItemName":"Tramadol"}]},{"id":"9ed9a9fb-0b52-50ef-8980-c1303531094d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4fd6ab13-09e0-57f4-a265-464eeab8c835","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"3eb7f136-ffd0-5f27-b2d1-21b49247596d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"606fc7bf-da44-5385-95f8-0139b3c57ef7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9fc3997f-80c3-5333-b5bd-3b3a518bdde6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"74708745-26ce-5fd4-8c02-67ba25b5a355","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4f5855b4-c905-54ca-b02a-820f8fdd4a4a","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f09723db-fe39-5bbd-b643-d063fcd61d42","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"855f03f8-54cb-5675-a6b8-aeb8064288d7","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"0afa89fa-71a1-53a3-a61d-d4526ac1fc46","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 7988b902-169b-47d3-a720-b17daba0adcc --><h3>Previous changes</h3><!-- end field 7988b902-169b-47d3-a720-b17daba0adcc -->","summary":null,"htmlStringContent":"<!-- begin item 48677da4-3331-4951-8559-d901336a11bf --><!-- begin field 5270b1bf-7ae6-489a-8a6d-702bea696e61 --><p><strong>May 2019 </strong>— minor update. Dysphagia added as an adverse effect of gabapentin. </p><p><strong>March 2019 </strong>— minor update. Gabapentin and pregabalin have now be rescheduled as Schedule 3 Controlled Drugs.</p><p><strong>October 2018</strong> — minor update. References to amitriptyline being off-label removed. </p><p><strong>September 2017 </strong>— minor update. Change to adverse effects for gabapentin to reflect changes to the manufacturer's Summary of Product Characteristics regarding respiratory disorders.</p><p><strong>July 2017 </strong>— minor update. Addition to adverse effects for pregabalin to reflect changes to the manufacturer's Summary of Product Characteristics.</p><p><strong>June 2015 </strong>— minor update. Based on an update to the manufacturer's Summary of Product Characteristics, hyponatraemia has been included as a possible adverse effect of gabapentin.</p><p><strong>April 2015</strong> — minor updates:</p><ul><li>Correction to the prescribing information for tramadol with regards to the legal requirements for handwriting prescriptions.</li><li>The text regarding the use of tramadol in pregnancy and breastfeeding has been removed and a link to the CKS topic on <em>Analgesia</em> has been provided.</li></ul><p><strong>June 2014 </strong>— minor update. Update to the text to reflect the fact that tramadol has been reclassified to a schedule 3 controlled drug.</p><p><strong>January 2014 to February 2014 </strong>— reviewed. A literature search was conducted in January 2014 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The following changes were made:</p><ul><li>The management section has been rewritten to reflect the recommendations in the updated NICE guideline: <em>Neuropathic pain — pharmacological management. The pharmacological management of neuropathic pain in adults in non-specialist settings</em><em>.</em></li><li>The prescribing information section has been amended in line with the updated NICE guideline referenced above: prescribing information sections for duloxetine and capsaicin cream have been added, and prescribing information sections for drugs no longer recommended by NICE (imipramine, nortriptyline, and lidocaine plasters) have been removed.</li><li>The evidence section has been rewritten to reflect the changes in the updated NICE guideline referenced above.</li></ul><p><strong>August 2012 </strong>— minor update. Minor typographical error corrected.</p><p><strong>May to September 2010 </strong>— topic updated. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>January 2009 </strong>— minor update. Drug safety advice from the MHRA (Medicines and Healthcare products Regulatory Agency) that all antiepileptic drug treatment (including carbamazepine and gabapentin) is associated with a small risk of suicidal thoughts and behaviour has been added. Issued in February 2009.</p><p><strong>September to December 2008 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 5270b1bf-7ae6-489a-8a6d-702bea696e61 --><!-- end item 48677da4-3331-4951-8559-d901336a11bf -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}